octreotide acetate / Generic mfg. - LARVOL DELTA

Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study (ESMO 2026) - No abstract available

Clinical • P2 data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology

Refractory Parastomal Variceal Bleeding Managed With Trans-Splenic Portal Vein Recanalization and TIPS: A Case Report (ACG 2026) - "He was discharged on anticoagulation, nadolol, and long-acting octreotide...(B). Splenic venogram after successful mechanical thrombectomy and placement of the transjugular intrahepatic portosystemic shunt (TIPS)."

Case report • Clinical • Colorectal Cancer • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Immunology • Portal Hypertension • Solid Tumor • Thrombosis

Hiding in Plain Sight: Metastatic Neuroendocrine Tumor Masquerading as GERD and Functional GI Symptoms in a Young Woman (ACG 2026) - "The patient was managed as a gastropancreatic NET of unknown primary per NCCN guidelines and was initiated on octreotide LAR 30 mg intramuscularly every 4 weeks...This low proliferation index is consistent with WHO Grade 1 (G1) NET (Ki-67 <3% = G1; some series accept up to 5% within G1 range). Confirm with exact count for grading purposes."

Clinical • Metastases • CNS Disorders • Depression • Dyspepsia • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Mood Disorders • Neuroendocrine Tumor • Oncology • Otorhinolaryngology • Solid Tumor • CHGA • SSTR

Clinical Application of Functional Imaging and Peptide Receptor Radionuclide Therapy (IASGO 2026) - "The ongoingphase 3 NETTER-3 trial extends this to newly diagnosed grade 1-2 (Ki-67 <10%) GEP-NET with high tumorburden, comparing Lu-177 DOTATATE plus octreotide LAR with octreotide LAR. Amino acid co-infusion protects the kidneys, but a delayed decline in renalfunction remains the main concern with repeated treatment, so cumulative renal dose should guideretreatment. In Korea, Lu-177 DOTATATE is reimbursed for later-line use and earlier access is beingsought; alpha therapy with Ac-225 DOTATATE (ACTION-1) is the next step for refractory disease."

Clinical • Gastrointestinal Neuroendocrine Tumor • Hematological Disorders • Neuroendocrine Tumor • Solid Tumor • Thrombocytopenia • SSTR

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). (PubMed, J Clin Oncol) - "Axitinib significantly increased PFS per BICR assessment and ORR both per investigator and BICR assessment compared with placebo, although the primary study end point was not met. Toxicity profile was manageable with no new safety concerns."

Clinical • Journal • P3 data • Cardiovascular • Gastrointestinal Neuroendocrine Tumor • Hypertension • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids. (PubMed, Front Endocrinol (Lausanne)) - P1 | "Although this study was not designed to evaluate therapeutic efficacy, the pharmacokinetic and pharmacodynamic profile of TE-8214 supports further clinical evaluation in patients with neuroendocrine tumors or acromegaly. https://clinicaltrials.gov/, identifier NCT06372652."

Clinical • Journal • Acromegaly • Endocrine Disorders • Oncology • Pain • Solid Tumor • IGF1 • SSTR • SSTR2

A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P2 trial • Acromegaly • Endocrine Disorders • IGF1

Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Lu-Dotatate treatment did not significantly improve median overall survival versus high-dose long-acting octreotide. Despite final overall survival not reaching statistical significance, the 11·7 month difference in median overall survival with Lu-Dotatate treatment versus high-dose long-acting octreotide alone might be considered clinically relevant. No new safety signals were reported during long-term follow-up."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Endocrine Cancer • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. (ASCO-GI 2024) - P3 | "177Lu-DOTATATE significantly prolonged PFS and demonstrated a clinically meaningful ORR, compared with high-dose octreotide LAR, in pts with newly diagnosed advanced G2 and G3 GEP-NETs. Safety was in line with the established profile of 177Lu-DOTATATE. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice."

Clinical • Late-breaking abstract • Metastases • P3 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study (ESMO-GI 2024) - P3 | "This preplanned subgroup analysis examined efficacy by NET grade (G2, G3) and NET origin (pancreas, small intestine [SI]). Pts were randomized to receive 4 cycles of 177Lu-DOTATATE (4 × 7.4 GBq) + 30 mg octreotide long-acting release (LAR) every 8 weeks (Q8W) during 177Lu-DOTATATE treatment then Q4W (177Lu-DOTATATE arm; n=151), or 60 mg octreotide LAR Q4W (control arm; n=75). 1L 177Lu-DOTATATE efficacy was maintained across NET grades (G2, G3) and locations (pancreas, SI) and it should be considered a standard of care for this pt population."

Clinical • Metastases • P3 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

177Lu-DOTATATE versus high-dose long-acting octreotide for somatostatin receptor-positive advanced GEP-NETs: A multicenter, randomised, open-label, positive-controlled phase III study (ESMO Asia 2025) - P3 | "177Lu-DOTATATE had an acceptable safety profile in GEP-NETs pts with PFS improvement versus high-dose long-acting octreotide."

Clinical • Late-breaking abstract • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • SSTR

HIGHER DOSES OF OCTREOTIDE LONG ACTING-RELEASE DO NOT PROVIDE ADDITIONAL BENEFIT IN GASTROINTESTINAL ANGIODYSPLASIA-RELATED BLEEDING (UEGW 2026) - No abstract available

Cardiovascular

OCTREOTIDE LAR IN THE TREATMENT OF GASTROINTESTINAL ANGIODYSPLASIAS – A SINGLE-CENTRE RETROSPECTIVE COHORT STUDY (UEGW 2026) - No abstract available

Retrospective data • Cardiovascular

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. (PubMed, EClinicalMedicine) - P3 | "These findings support the use of first-line 177Lu-DOTATATE for patients with advanced, well-differentiated, higher grade 2-3 (Ki67 ≥10% and ≤55%), somatostatin receptor-positive GEP-NETs, and for whom chemotherapy is not considered the most appropriate treatment option, regardless of NET grade (2/3) or origin (pancreas/gastrointestinal). Advanced Accelerator Applications, a Novartis Company."

Journal • P3 data • Retrospective data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

Octreotide as Adjunctive Therapy for Catecholamine-Secreting Pheochromocytoma and Paraganglioma. (PubMed, J Clin Endocrinol Metab) - "Octreotide treatment was associated with biochemical, hemodynamic, and metabolic improvement and may serve as a useful adjunct in selected patients, particularly as a bridge to surgery and during perioperative preparation."

Journal • Diabetes • Metabolic Disorders • Oncology • Solid Tumor • SSTR

Long-Term Results of Long-Acting Somatostatin Analog Therapy in Children with Congenital Hyperinsulinism. (PubMed, J Clin Res Pediatr Endocrinol) - "Transient elevations in liver enzymes and cholelithiasis were the most frequently observed side effects, indicating a safety profile comparable to that of short-acting octreotide. These results suggested that octreotide-LAR therapy is an effective and safe treatment option for diazoxide-unresponsive patients with CHI."

Journal • CNS Disorders • Developmental Disorders • Epilepsy • Gastroenterology • Hypoglycemia • Severe Hypoglycemia

CHEK2 germline gene variant in a patient with a somatotrophinoma and primary hyperparathyroidism: a novel MEN1-like syndrome? (PubMed, Endocr Oncol) - "The patient underwent transsphenoidal resection of the pituitary tumour followed by gamma-knife radiosurgery and received long-acting octreotide every four weeks...This is the first reported case of a CHEK2 germline mutation associated with somatotrophinoma, PHPT, and collagenoma, mimicking the clinical MEN1 syndrome. These findings expand the spectrum of possible CHEK2-associated neoplasia and highlight the need to consider CHEK2 as a possible candidate gene in patients with MEN1-like syndromes when common mutations have been excluded."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • CDKN1B • CHEK2 • IGF1 • PRKAR1A

SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov) - P3 | N=332 | Active, not recruiting | Sponsor: Camurus AB | Trial completion date: Jul 2028 ➔ Nov 2028 | Trial primary completion date: Jul 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Fourteen-year bridge to cure in occult ectopic ACTH syndrome: resection of a 3-mm pulmonary carcinoid. (PubMed, JCEM Case Rep) - "Based on a positive octreotide challenge test, she received long-acting release octreotide for over a decade, achieving sustained biochemical stability...This may also have preserved SSTR2 expression, potentially by mitigating cortisol-induced receptor downregulation, facilitating its eventual localization. This report shows that meticulous multidisciplinary communication during unrelated surgical procedures is indispensable for identifying radiologically occult lesions."

Journal • Breast Cancer • Cushing’s Disease • Endocrine Disorders • Oncology • Solid Tumor • SSTR • SSTR2

LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort. (PubMed, J Neurol Surg B Skull Base) - "Concurrent octreotide long-acting release (Oct-LAR) (29/60.4%) and cabergoline (20/41.7%) were also common. THC was longer for SFRT patients, with no statistical differences. Concurrent treatment did not impact outcomes."

Journal • Retrospective data • Acromegaly • Endocrine Disorders • Oncology

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report. (PubMed, Front Oncol) - "The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor • SSTR • SSTR2

A Young Man With Pituitary Carcinoma: A Case Report (ENDO 2026) - "Despite 6 prior surgeries, temozolomide, and cisplatin–etoposide chemotherapy, the tumor progressed, ultimately measuring 5.9 × 3.6 × 3.4 cm with cavernous sinus and third ventricular invasion...The patient was subsequently treated with octreotide LAR 20 mg every 28 days, bevacizumab 10 mg/kg every 2 weeks, and lomustine 90 mg/m2 every 6 weeks, achieving a 25–50% radiologic reduction and decline in IGF-1 from 1,233 to 870 ng/mL after 3 months of therapy... This case illustrates an extraordinarily aggressive pituitary carcinoma with sarcomatous transformation, resistant to standard therapies yet partially responsive to a bevacizumab–lomustine regimen. To our knowledge, fewer than 15 similar cases have been reported since 1980. The coexistence of ATRX and GNAS mutations, transformation from a nonfunctioning to a secreting tumor, and partial therapeutic response highlight the biological complexity of these rare entities and underscore the importance of integrated..."

Case report • Clinical • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Sarcoma • Solid Tumor • ATRX • GNAS • IGF1

Primary Ovarian Neuroendocrine Neoplasm With Carcinoid Syndrome and Carcinoid Heart Disease. (PubMed, Ochsner J) - "Preoperative management included long-acting octreotide, niacin, and guideline-directed heart failure therapy, followed by tumor resection...Primary ovarian neuroendocrine neoplasms can cause carcinoid syndrome and right-sided valvulopathy without liver metastasis, likely because ovarian venous drainage bypasses hepatic first-pass metabolism. Multidisciplinary care enables prompt diagnosis, preoperative stabilization, definitive resection, and coordinated surveillance."

Journal • Carcinoid Syndrome • Carcinoid Tumor • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Endocrine Cancer • Heart Failure • Hepatocellular Cancer • Oncology • Ovarian Cancer • Pulmonary Disease • Solid Tumor • CHGA

Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial (ENDO 2026) - P3 | "CAM2029 is a novel, long-acting octreotide subcutaneous depot for self-administration. CAM2029 maintained stable mean AIS Overall Scores (SD) in patients with later assessments (W48, 3.6 [3.0]; W52/EOCP, 3.7 [3.1]). Conclusion Long-term CAM2029 maintains stable disease control over a 4W dosing interval and can reduce the waning control seen with other injectable SRLs."

Acromegaly • Endocrine Disorders • IGF1 • SSTR

Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension (ENDO 2026) - "CAM2029 is a long-acting, octreotide subcutaneous depot, recently approved in Europe and the UK. CAM2029 maintains biochemical control, sustains symptom control and enhances treatment satisfaction. When loss of control follows switch to SoC treatment, biochemical control can be regained with CAM2029."

Clinical • Acromegaly • Endocrine Disorders • IGF1